1 study found for:    19038878 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide;   Drug: Etoposide;   Drug: Alemtuzumab;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Rituximab;   Drug: Vincristine

Indicates status has not been verified in more than two years